Circulating Natriuretic Peptides in Cats with Heart Disease
- 1 January 2008
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 22 (1) , 96-105
Abstract
Background: Circulating natriuretic peptide concentrations are increased in cats with myocardial dysfunction. Hypothesis: Serum N-terminal fragment of proatrial natriuretic peptide (NT-proANP) and NT-probrain natriuretic peptide (proBNP) concentrations may predict the presence of heart disease (HD) and congestive heart failure (CHF). A positive relationship is also predicted among natriuretic peptide (NP) concentrations, a noninvasive estimate of left ventricular filling pressure (E/Ea), and an echocardiographic measure of left atrial (LA) size (LA/aortic diameter [Ao]). Methods: Serum NP concentrations were measured in 28 healthy control and 50 study cats using sandwich enzyme immunoassays. The study group comprised cats, with HD but no CHF (HD − CHF, n = 17) and cats with CHF (HD + CHF, n = 33). The relationship among NP concentrations, LA size, and E/Ea was examined. The ability of NP to distinguish control from study cats, and HD − CHF from HD + CHF cats, was explored using receiver operator curve analysis. Results: NP concentrations were significantly lower in control than in study cats (P= .0001). The NT-proBNP concentrations were positively correlated with LA/Ao ratio (ρ= 0.34; P= .02) and with E/Ea ratio (ρ= 0.68; P < .05). An NT-proBNP concentration of 49 fmol/mL gave a sensitivity and specificity of 100 and 89.3%, respectively, for correctly distinguishing 96.2% of control from study cats. Pairwise comparisons of the areas under the curve identified a statistically significant difference (P= .011) between NT-proANP and NT-proBNP to distinguish control from study cats. NT-proANP and NT-proBNP concentrations were significantly higher in HD + CHF cats than in HD − CHF cats (P= .0023 and .0001, respectively). Conclusions: Serum concentrations of NT-proANP and particularly NT-proBNP were different in healthy control cats, asymptomatic cats with HD, and cats with CHF, suggesting that measurement of NP concentrations may prove clinically useful as an initial screening test for cats with suspected cardiac disease.Keywords
This publication has 36 references indexed in Scilit:
- Survival of Cats with Naturally Occurring Chronic Renal Failure Is Related to Severity of ProteinuriaJournal of Veterinary Internal Medicine, 2006
- Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy–causing mutations in the β-myosin heavy chain, α-tropomyosin, and myosin-binding protein C genesAmerican Heart Journal, 2006
- Plasma amino-terminal pro–B-type natriuretic peptide quantification in hypertrophic cardiomyopathyAmerican Heart Journal, 2005
- Cardiovascular and metabolic effects of natriuretic peptidesFundamental & Clinical Pharmacology, 2005
- Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 2005
- Diagnostic Potential of Natriuretic Peptides in the Occult Phase of Golden Retriever Muscular Dystrophy CardiomyopathyJournal of Veterinary Internal Medicine, 2004
- Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT)JACC, 2004
- Neuroendocrine evaluation of cardiac diseaseVeterinary Clinics of North America: Small Animal Practice, 2004
- Recommendations for Standards in Transthoracic Two-Dimensional Echocardiography in the Dog and CatJournal of Veterinary Internal Medicine, 1993
- Atrial Natriuretic Peptide and Atrial Pressure in Patients with Congestive Heart FailureNew England Journal of Medicine, 1986